AzTrials
AzTrials

OvulationPhase 4PRO-TRIGGERNCT07466199

Exogenous Progesterone as Ovulation Trigger

A Phase 4 study testing Vaginal micronized progesterone in people with Ovulation and Ovarian Function, run by Instituto Valenciano de Infertilidade de Lisboa at 1 site in Portugal.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

The goal of this clinical trial is to learn whether the sudden administration of vaginal micronized progesterone during the late follicular phase can trigger an LH surge and reactivation of oocyte meiosis in healthy oocyte donors aged 18 to 33 undergoing a mild ovarian stimulation cycle. Read more about this study

Who is it for?
Ages 18 to 33 years, women only
What is being tested?
Vaginal micronized progesterone
Could I receive a placebo?
No, everyone receives an active treatment
How many people
10 participants
Where
1 sitePortugal
Study dates
Jul 2026to Aug 2026
Phase
Phase 4
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 33 years
  • Women only
  • No healthy volunteers
  • Adult

Who may be able to join

  • Informed Consent Form dated and signed correctly prior to the performance of any study procedure.
  • Oocyte donors aged >17 and <34 years old in the moment of the recruitment.
  • Patients with regular menstrual cycles (between 25 to 35 days long).
  • Generally healthy women with no history of endocrine disorders (e.g., polycystic ovary syndrome (PCOS) or significant systemic disease).
  • Body Mass Index (BMI) between 18.5 and 28.

Who cannot join

  • Presence of ovarian cyst(s) detected on the baseline (initial) ultrasound examination.
  • Untreated endocrine conditions (polycystic ovary syndrome (PCOS), uncontrolled thyroid dysfunction and hyperprolactinemia).
  • Hypogonadotropic or hypergonadotropic hypogonadism.
  • Known hypersensitivity or clinical contraindication to the administration of vaginal progesterone or its excipients. This includes, but is not limited to: active deep vein thrombosis or thromboembolic disorders, known or suspected estrogen- or progesterone-dependent neoplasia, undiagnosed abnormal genital bleeding, porphyria, or severe hepatic dysfunction. Additionally, patients with anatomical abnormalities of the vagina that preclude the proper insertion or absorption of the vaginal insert are excluded.
  • Any condition contraindicating vaginal ultrasound and/or vaginal oocyte retrieval.These include: active pelvic inflammatory disease (PID), acute vaginal or cervical infection, or presence of pelvic malignancies. Patients with significant anatomical distortions or vascular anomalies in the pelvic region that, in the investigator's opinion, would make oocyte retrieval technically unfeasible or pose an unacceptable risk of hemorrhage or injury to adjacent organs, are also excluded.
  • Use of hormonal contraceptives (oral, patch, or ring) or GnRH analogues within the month preceding the study. Note: Participants who have discontinued these or other prohibited medications for a period of at least 30 days are eligible for rescreening starting at Visit 1.
  • Participation in any other ongoing clinical trial or use of investigational drugs within the last 30 days.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Portugal1 site
  • Instituto Valenciano de Infertilidade (IVI Lisboa)

    Lisbon, 1800-282

    Samuel Ribeiro, +351 218 503 210, Samuel.Ribeiro@ivirma.com

Other trials in Portugal

About this study

Official title: Exogenous Progesterone as Ovulation Trigger - a Pilot Study

The goal of this clinical trial is to learn whether the sudden administration of vaginal micronized progesterone during the late follicular phase can trigger an LH surge and reactivation of oocyte meiosis in healthy oocyte donors aged 18 to 33 undergoing a mild ovarian stimulation cycle. The main question it aims to answer is:

  • Does progesterone administered in the late follicular phase induce an LH surge and subsequent oocyte meiosis reactivation?
Read more

Participants will:

  • Undergo a mild ovarian stimulation with 75 IU of follitropn alfa
  • Start vaginal micronized progesterone (400 mg every 12 hours) once at least one follicle reaches 15 mm
  • Have blood samples collected to measure hormone levels before and after progesterone administration
  • Undergo oocyte retrieval 35-36 hours after the progesterone trigger

This is a low-intervention, single-center pilot study including approximately 10 oocyte donors.

Read the detailed description

Ovulation is triggered by the sudden surge of gonadotropins, FSH and mainly LH, which occurs during the late follicular phase. This LH surge creates the environment for follicular eruption by increasing the activity of the proteolytic enzymes that weaken the ovarian wall leading to follicle rupture. However, the stimuli leading to the LH surge arises are not clear yet. The current scientific paradigm postulates that high levels of estradiol at the end of the follicular phase may, by positive feedback, stimulate the sudden release of gonadotropins. However, several factors seem to contradict this theory. Ovarian stimulation cycles with high doses of gonadotropins in high responders leads to high levels of estradiol in an early phase without incurring in ovulation until the late follicular phase. Thus, there may be a narrow window in the late follicular phase in which ovulation may occur. As such, the sustained high levels of estrogen in the late follicular phase could be responsible for the LH surge. Nevertheless, studies using high dose exogenous estradiol in late follicular phase showed that there was no impact on gonadotrophin surge or ovulation. On the other hand, studies based on ovarian stimulation cycles with letrozole, with much lowers serum estrogen levels, showed that the ovulatory peak occurs in the same way, even in the presence of very low or decreasing levels of estradiol. Interestingly, patients treated with letrozole may present higher levels of LH at peak. Hence, the role of estrogens in inducing the gonadotrophin peak is yet unclear.

Progesterone may eventually have a role in the physiological induction of ovulation. Long-standing studies have shown that an increase in serum progesterone levels precedes the LH peak and supports the action of the LH on the follicle rupture. Evidence has long shown that elevated serum progesterone levels during controlled ovarian stimulation are associated with a considerable risk of earlier ovulation. Likewise, previous studies have shown that the administration of intramuscular progesterone during the late follicular phase leads to the onset of an endogenous LH peak, both following controlled ovarian stimulation and in a natural cycle. Also supporting these theories is a new protocol of endometrial preparation for frozen embryo transfer presented by our research group. This strategy, in which, in an advanced follicular phase, after establishing adequate endometrial thickness on ultrasound, exogenous administration of vaginal micronized progesterone is started, simulating a second phase of the cycle, with endogenous production of estrogens and exogenous administration of progesterone. Curiously, in the first obstetric assessment the presence of an adnexal mass is frequently been noted, probably corresponding to a corpus luteum. If so, exogenous progestins may have acted as a possible trigger of ovulation.

Contrary to these theories is the fact that the exogenous administration of progestins for pituitary inhibition has been used for decades as a method of contraception. Thus, there may be a narrow window of time in the late follicular phase during which the pituitary gland is sensitive to the positive feedback effect of progesterone, leading to sudden release of gonadotropins. This may eventually be explained by the effect of the rising levels of estradiol during the follicular phase, which may prime the hypothalamus for a progesterone-induced gonadotropin surge. Another possibility is that sustained use of exogenous progestins may lead to desensitization of pituitary receptors, while in the presence of low serum progesterone levels, the receptors maintain sensitivity and the sudden increase of this hormone has a positive feedback effect on the pituitary gland.

Progestins may be administered by various routes. Vaginal micronized progesterone is a convenient form of administration and results in rapid and efficient absorption, with peak serum concentrations achieved within four to six hours.

With this study, the investigators intend to evaluate whether the sudden administration of exogenous progesterone may lead to LH peak, with resulting reactivation of oocyte meiosis.

Being tested
Vaginal micronized progesterone
Keywords
Trigger, Oocyte Donation, Progesterone, Oocyte Maturation, Luteinizing Hormone, LH Surge, Oocyte Retrieval, Oocyte Meiosis, Late Follicular Phase, Endocrinological profile

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Vaginal micronized progesteroneDrug

    Also called Cyclogest® 400 mg

    This intervention consists of administering vaginal micronized progesterone at a dose of 400 mg every 12 hours to induce final oocyte maturation. The intervention is initiated once at least one follicle reaches a diameter of 15 mm during controlled ovarian stimulation with recombinant FSH. Progesterone administration continues until the morning of oocyte retrieval.

Study groups in NCT07466199
Study groupRoleWhat they receive
Oocyte donorsExperimentalThis arm includes 10 healthy oocyte donors undergoing an ovarian stimulation cycle with 75 IU of recombinant FSH, followed by progesterone-induced ovulation triggering. All participants receive recombinant FSH starting on cycle days 1-3, following spontaneous mentsrual bleeding. Once at least one follicle reaches 15 mm, final oocyte maturation is induced with vaginal micronized progesterone 400 mg every 12 hours. Hormonal monitoring and ultrasound assessments are performed as part of standard care. Oocyte retrieval is performed 35-36 hours after "progesterone-induced ovulation triggering" by transvaginal aspiration. Progesterone will be kept until the morning of the day of oocyte retrieval.
Receives: Drug: Vaginal micronized progesterone

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of mature oocytes

    The number of mature oocytes obtained during the oocyte retrieval procedure. Retrieved follicular aspirates will be examined to identify and isolate cumulus-oocyte complexes, which will be assessed for maturity according to standard embryology laboratory procedures. The count of mature oocytes reflects oocyte meiosis reactivation following progesterone-induced ovulation triggering.

    Measured: 35-36 hours after progesterone initiation

Secondary outcomes (3)
  1. Endocrinological profile (E2, P4, FSH, LH)

    Serum hormone levels (estradiol, progesterone, FSH and LH) collected via blood sample (as part of standard clinical practice)

    Measured: 12 hours after progesterone initiation

  2. Endocrinological profile (E2, P4, FSH, LH)

    Serum hormone levels (estradiol, progesterone, FSH and LH) collected via blood sample (as part of standard clinical practice)

    Measured: 35-36 hours after progesterone initiation

  3. Total number of oocytes retrieved

    The total number of oocytes retrieved during the transvaginal oocyte aspiration procedure are counted. Oocyte retrieval is conducted according to routine clinical practice.

    Measured: 35-36 hours after progesterone initiation

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Mar 2026
  2. Study startJul 2026 (estimated)
  3. Primary completionAug 2026 (estimated)
  4. Study completionAug 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Model description
This study uses a single-group including 10 oocyte donors. All participants follow the same ovarian stimulation protocol and receive vaginal micronized progesterone as the triggering intervention. Progesterone administration is initiated once at least one follicle reaches 15 mm. Hormonal monitoring and ultrasound assessments are performed as part of standard care, and oocyte retrieval takes place 35-36 hours after progesterone initiation. There is no control or comparison group; the study is designed as a proof-of-concept evaluation of progesterone as an ovulation trigger.
Masking
None (open label)
Enrolment
10 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07466199
Sponsor's protocol ID
2504-LIS-054-AN
Acronym
PRO-TRIGGER
Status last verified
Jun 2026
First submitted
6 Mar 2026
Last updated
4 Jun 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Vaginal micronized progesterone in people with Ovulation and Ovarian Function, run by Instituto Valenciano de Infertilidade de Lisboa at 1 site in Portugal.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 4 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Portugal. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Ana Raquel Neves (+351 218 503 210, Ana.Neves@ivirma.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of mature oocytes (time frame: 35-36 hours after progesterone initiation). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Jun 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in